A possible Apollo collaboration

Current status: proposed only. Programmable Bio has no signed MoU, contracted EHR access, biospecimen access, patient access, exclusivity, or right to use Apollo's name as a partner.

A future collaboration could connect Programmable Bio's operational autonomous lab with consented, ethics-approved clinical research programs. Any such work would require a negotiated agreement defining scope, lawful purpose, consent, data roles, security, publication, IP, economics, and oversight.

Principles for a responsible proposal

Purpose-limited access

Every dataset or biospecimen cohort tied to an approved research question, consent scope, and retention period.

Data minimization

Prefer controlled, federated, or de-identified analysis. Do not move raw clinical data simply because it is technically possible.

Independent oversight

Institutional ethics review, scientific governance, audit trails, and documented responsibility for each party.

No implied exclusivity

Exclusivity, commercial rights, and branding would exist only if expressly agreed in signed documents.

Illustrative collaboration structure

WorkstreamPossible Apollo rolePossible Programmable Bio role
Pilot validation cohortEthics-approved sample and phenotype governanceAutomated assay execution and structured experimental data
Biomarker studyClinical question, cohort definition, investigator oversightAssay design, reproducible execution, analytical tooling
Federated analysisApproved compute and access controlsContainerized analysis and provenance records
Joint translationClinical interpretation and study pathwayExperimental iteration and model-ready evidence

Milestones before any public partnership claim

  1. Named executive and scientific sponsors on both sides
  2. Signed MoU or definitive research agreement
  3. Defined pilot, ethics path, consent basis, and data-governance design
  4. Approved public wording and trademark use
  5. Measured pilot outcomes before commercial claims

Fallback path

The autonomous-lab business does not depend on Apollo. The Hyderabad lab can scale standardized validation independently. If an Apollo agreement is not reached, clinical-context programs can be pursued later with other hospitals, biobanks, or research institutions under equivalent governance.